Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21291454 | 0.98 | EGLN1 (0.38) | EGLN1KLKB1KDM4EALDH1A1MAPT | |
| SCHEMBL21291411 | 0.98 | EGLN1 (0.38) | EGLN1KLKB1KDM4EALDH1A1MAPT | |
| SCHEMBL24221965 | 0.98 | EGLN1 (0.38) | EGLN1KLKB1KDM4EALDH1A1MAPT | |
| SCHEMBL19984573 | 0.85 | EGLN1 (0.39) | EGLN1KLKB1KDM4EALDH1A1MAPT | |
| SCHEMBL19984760 | 0.85 | EGLN1 (0.39) | EGLN1KLKB1KDM4EALDH1A1MAPT | |
| SCHEMBL19984572 | 0.85 | EGLN1 (0.39) | EGLN1KLKB1KDM4EALDH1A1MAPT | |
| SCHEMBL21291446 | 0.83 | EGLN1 (0.38) | EGLN1KLKB1KDM4EALDH1A1MAPT | |
| SCHEMBL21291452 | 0.82 | EGLN1 (0.38) | EGLN1KLKB1KDM4EALDH1A1MAPT | |
| SCHEMBL21291407 | 0.80 | EGLN1 (0.42) | EGLN1KLKB1ROCK2 | |
| SCHEMBL18667414 | 0.79 | EGLN1 (0.44) | EGLN1ALDH1A1MAPTSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | EGLN1 3738/4885KLKB1 2491/4885KDM4E 2469/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | EGLN1 3738/4885KLKB1 2491/4885KDM4E 2469/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | EGLN1 3738/4885KLKB1 2491/4885KDM4E 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.